Cargando…

Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis

BACKGROUND: In adult patients with arthritis, use of the tumor necrosis factor (TNF) inhibitor etanercept (ETN) is often associated with a reduction in the utilization of co-medications, particularly steroids. Comparatively little is known about the utilization of co-medications when ETN is initiate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khraishi, Majed, Millson, Brad, Woolcott, John, Jones, Heather, Marshall, Lisa, Ruperto, Nicolino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734296/ https://www.ncbi.nlm.nih.gov/pubmed/31500631 http://dx.doi.org/10.1186/s12969-019-0358-x

Ejemplares similares

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
por: Öman, Anders, et al.
Publicado: (2021)

Current Medical Treatments for Juvenile Idiopathic Arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2011)

Distinct Effects of Methotrexate and Etanercept on the B Cell Compartment in Patients With Juvenile Idiopathic Arthritis
por: Glaesener, Stephanie, et al.
Publicado: (2014)

Current evidence for the medical treatments of systemic juvenile idiopathic arthritis
por: Ruperto, Nicolino
Publicado: (2014)

Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
por: Levälampi, Tiina, et al.
Publicado: (2023)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

Challenges in the management of juvenile idiopathic arthritis with etanercept
por: Pain, Clare E, et al.
Publicado: (2009)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Etanercept treatment in juvenile idiopathic arthritis: The Polish registry
por: Żuber, Zbigniew, et al.
Publicado: (2011)

The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014)

Clinical remission in juvenile idiopathic arthritis after termination of etanercept
por: Postępski, Jacek, et al.
Publicado: (2012)

PReS-FINAL-2184: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate
por: Ruperto, N, et al.
Publicado: (2013)

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
por: Livermore, P, et al.
Publicado: (2016)

Influence of etanercept on leptin and ghrelin secretion in children with juvenile idiopathic arthritis
por: Maciejewska-Paszek, Izabela, et al.
Publicado: (2017)

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
por: Lovell, Daniel J, et al.
Publicado: (2020)

Predictors of response to methotrexate in juvenile idiopathic arthritis
por: Albarouni, Mohamed, et al.
Publicado: (2014)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Miettunen, Paivi, et al.
Publicado: (2018)

Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
por: Verazza, Sara, et al.
Publicado: (2016)

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
por: Foeldvari, Ivan, et al.
Publicado: (2019)

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study
por: Horneff, Gerd, et al.
Publicado: (2014)

Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Immunomodulatory actions of methotrexate on T cells in juvenile idiopathic arthritis
por: Ćalasan, Maja Bulatović, et al.
Publicado: (2012)

Genetic determinants for methotrexate response in juvenile idiopathic arthritis
por: Pastore, Serena, et al.
Publicado: (2015)

Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis
por: Falvey, Sonja, et al.
Publicado: (2017)

Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
por: Southwood, TR, et al.
Publicado: (2008)

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Beukelman, Timothy, et al.
Publicado: (2021)

Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis
por: Keystone, Edward C., et al.
Publicado: (2016)

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
por: Prince, FHM, et al.
Publicado: (2008)

The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
por: Trachana, M, et al.
Publicado: (2011)

In vitro effects of etanercept on the development of different T cell subsets in patients with juvenile idiopathic arthritis
por: Cimaz, Rolando, et al.
Publicado: (2011)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
por: Klotsche, Jens, et al.
Publicado: (2021)

Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis
por: Kahn, Robin, et al.
Publicado: (2016)

Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review
por: Horneff, Gerd, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lab621rhchiogusnsa49rdku59